A medical device that is at least partially formed of a novel metal alloy, which novel metal alloy improves the physical properties of the medical device.
대표청구항▼
1. A medical device that is at least partially formed of a metal alloy which improves the strength and ductility of the medical device, said metal alloy including at least about 90 weight percent of a solid solution of a rhenium and molybdenum alloy, said metal alloy including at least about 40 weig
1. A medical device that is at least partially formed of a metal alloy which improves the strength and ductility of the medical device, said metal alloy including at least about 90 weight percent of a solid solution of a rhenium and molybdenum alloy, said metal alloy including at least about 40 weight percent rhenium and at least about 40 weight percent molybdenum, said metal alloy having a controlled amount of nitrogen, oxygen and carbon so as to reduce micro-cracking in said metal alloy, a nitrogen content of said metal alloy less than a combined content of oxygen and carbon in said metal alloy, said metal alloy including an oxygen to nitrogen atomic ratio of at least about 1.2:1, said metal alloy including a carbon to nitrogen atomic ratio of at least about 2:1. 2. The medical device as defined in claim 1, wherein said metal alloy includes less than about 0.2 weight percent carbon, less than about 0.1 weight percent oxygen, and less than about 0.001 weight percent nitrogen. 3. The medical device as defined in claim 1, wherein said metal alloy has a carbon to oxygen atomic ratio of about 0.2-2:1. 4. The medical device as defined in claim 2, wherein said metal alloy has a carbon to oxygen atomic ratio of about 0.2-2:1. 5. The medical device as defined in claim 1, wherein said metal alloy includes at least about 99 weight percent of a solid solution, said solid solution including at least 95 weight percent rhenium and molybdenum and less than about 5 weight percent of a metal selected from the group consisting of titanium, yttrium, zirconium, or mixtures thereof. 6. The medical device as defined in claim 4, wherein said metal alloy includes at least about 99 weight percent of a solid solution, said solid solution including at least 95 weight percent rhenium and molybdenum and less than about 5 weight percent of a metal selected from the group consisting of titanium, yttrium, zirconium, or mixtures thereof. 7. The medical device as defined in claim 1, wherein said metal alloy having an average yield strength of at least about 70 ksi and an average ultimate tensile strength of at least about 60 ksi, said metal alloy having an average grain size is about 5.2-10 ASTM, said metal alloy having an average tensile elongation of at least about 25%, said metal alloy having an average hardness of at least about 60 (HRC) at 77° F., and said metal alloy having an average density of at least about 13.4 gm/cc. 8. The medical device as defined in claim 6, wherein said metal alloy having an average yield strength of at least about 70 ksi and an average ultimate tensile strength of at least about 60 ksi, said metal alloy having an average grain size is about 5.2-10 ASTM, said metal alloy having an average tensile elongation of at least about 25%, said metal alloy having an average hardness of at least about 60 (HRC) at 77° F., and said metal alloy having an average density of at least about 13.4 gm/cc. 9. The medical device as defined in claim 1, wherein said metal alloy metal alloy includes a plurality of second phase particles, said second phase particles including one or more particles selected from the group consisting of carbides, carbo-nitrides, and oxides. 10. The medical device as defined in claim 8, wherein said metal alloy metal alloy includes a plurality of second phase particles, said second phase particles including one or more particles selected from the group consisting of carbides, carbo-nitrides, and oxides. 11. The medical device as defined in claim 1, wherein said metal alloy having a nitrogen content of less than about 0.001 weight percent, said metal alloy having a carbon content of less than about 0.2 weight percent, having an oxygen content of less than about 0.1 weight percent, said metal alloy including an oxygen to carbon atomic ratio of about 0.2:1 and up to about 50:1, said metal alloy including an oxygen to nitrogen atomic ratio of at least about 1.2:1 and up to about 100:1, said metal alloy including a carbon to nitrogen atomic ratio of at least about 2:1 and up to about 100:1. 12. The medical device as defined in claim 10, wherein said metal alloy having a nitrogen content of less than about 0.001 weight percent, said metal alloy having a carbon content of less than about 0.2 weight percent, having an oxygen content of less than about 0.1 weight percent, said metal alloy including an oxygen to carbon atomic ratio of about 0.2:1 and up to about 50:1, said metal alloy including an oxygen to nitrogen atomic ratio of at least about 1.2:1 and up to about 100:1, said metal alloy including a carbon to nitrogen atomic ratio of at least about 2:1 and up to about 100:1. 13. The medical device as defined in claim 1, wherein said metal alloy includes about 45-50 weight percent rhenium and about 50-55 weight percent molybdenum. 14. The medical device as defined in claim 12, wherein said metal alloy includes about 45-50 weight percent rhenium and about 50-55 weight percent molybdenum. 15. The medical device as defined in claim 1, wherein at least one region of said medical device includes at least one biological agent. 16. The medical device as defined in claim 14, wherein at least one region of said medical device includes at least one biological agent. 17. The medical device as defined in claim 15, wherein said at least one biologocal agent includes trapidil, trapidil derivatives, taxol, taxol derivatives, cytochalasin, cytochalasin derivatives, paclitaxel, paclitaxel derivatives, rapamycin, rapamycin derivatives, GM-CSF, GM-CSF derivatives, or combinations thereof. 18. The medical device as defined in claim 1, wherein at least one region of said medical device includes at least one polymer. 19. The medical device as defined in claim 16, wherein at least one region of said medical device includes at least one polymer, said at least one polymer at least partially coats, encapsulates or combinations thereof said at least one agent. 20. The medical device as defined in claim 18, wherein said at least one polymer includes parylene, a parylene derivative, chitosan, a chitosan derivative, PLGA, a PLGA derivative, PLA, a PLA derivative, PEVA, a PEVA derivative, PBMA, a PBMA derivative, POE, a POE derivative, PGA, a PGA derivative, PLLA, a PLLA derivative, PAA, a PAA derivative, PEG, a PEG derivative, or combinations thereof. 21. The medical device as defined in claim 1, wherein said medical device includes at least one micro-structure in an outer surface of said medical device. 22. The medical device as defined in claim 14, wherein said medical device includes at least one micro-structure in an outer surface of said medical device. 23. The medical device as defined in claim 16, wherein said medical device includes at least one micro-structure in an outer surface of said medical device. 24. The medical device as defined in claim 20, wherein said medical device includes at least one micro-structure in an outer surface of said medical device. 25. The medical device as defined in claim 21, wherein said at least one micro-structure is at least partially formed of, includes, or combinations thereof, a material consisting of a polymer, an agent, or combinations thereof. 26. The medical device as defined in claim 5, wherein said metal alloy includes at least 0.05 weight percent titanium and up to about 1 weight percent titanium. 27. The medical device as defined in claim 5, wherein said metal alloy includes at least 0.05 weight percent zirconium and up to about 0.5 weight percent zirconium. 28. The medical device as defined in claim 5, wherein said metal alloy includes at least 0.05 weight percent zirconium and up to about 0.5 weight percent zirconium, a weight ratio of titanium to zirconium in said metal alloy is about 1-10:1. 29. The medical device as defined in claim 5, wherein said metal alloy includes at least 0.01 weight percent yttrium and up to about 0.3 weight percent yttrium.
Hirt Thomas ; Lohmann Dieter,CHX ; Hopken Jens,DEX ; Liu Qin, Amphiphilic, segmented copolymer of controlled morphology and ophthalmic devices including contact lenses made therefrom.
Iyer, Sriram S.; Kipshidze, Nicholas N.; Nikolaychik, Victor V., Apparatus and methods for preventing or treating failure of hemodialysis vascular access and other vascular grafts.
Buscemi Paul J. (Long Lake MN) Stejskal Elizabeth A. (St. Paul MN) Palme ; II Donald F. (Dayton MN) Wang Lixiao (St. Paul MN), Biodegradable drug delivery vascular stent.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
Ragheb, Anthony O.; Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Voorhees, III, William D.; Gershlick, Anthony H., Coated implantable medical device.
Lupton David Francis,DEX ; Schielke Jorg,DEX ; Weigelt Manfred,DEX ; Petermann Klaus,DEX ; Mix Eric,DEX ; Fornasiero Livio,DEX, Crucible for growing single crystals, process for making the same and use of the same.
Eury Robert P. (Cupertino CA) Garguilo Darlene (Fremont CA) Villareal Plaridel (San Jose CA), Drug loaded polymeric material and method of manufacture.
Wu Steven Z. ; Harish Sameer ; Sanders-Millare Deborra ; Guruwaiya Judy A., Implantable medical device having protruding surface structures for drug delivery and cover attachment.
Boylan, John F.; Boyle, William J.; Magrini, Kevin M.; Huter, Scott J., Medical devices configured from deep drawn nickel-titanium alloys and nickel-titanium clad alloys and method of making the same.
Tang Reginald T. (Somerset NJ) Mares Frank (Morris NJ) Boyle ; Jr. William J. (Morris NJ) Chiu Tin-Ho (Essex NJ) Patel Kundan M. (Morris NJ), Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lact.
Hermes Matthew E. (Easton CT) Muth Ross R. (Brookfield CT), Method for improving the storage stability of a polymeric article susceptible to hydrolytic degradation and resulting ar.
Dutta, Debashis; Wang, Chicheng; Rao, Kondapavulur T. V., Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers.
Kinsella James L. (Baltimore MD) Sollott Steven J. (Baltimore MD), Method of treating atherosclerosis or restenosis using microtubule stabilizing agent.
Askanazi Jeffrey (Haworth NJ) Katz David P. (Dobbs Ferry NY) Manner Tuula (Turku FIX), Methods and compositions for treating acute or chronic pain and drug addiction.
Singer Dinah S. (Chevy Chase MD) Kohn Leonard (Bethesda MD) Mozes Edna (Rehovot IL) Saji Motoyasu (Rockville MD) Weissman Jocelyn (Silver Spring MD) Napolitano Giorgio (Rockville MD) Ledley Fred D. (, Methods for assessing the ability of a candidate drug to suppress MHC class I expression.
Fischell Robert E. (14600 Viburnum Dr. Dayton MD 21036) Fischell David R. (71 Riverlawn Dr. Fair Haven NJ 07704) Fischell Tim A. (1018 Chancery Dr. Nashville TN 37215), Multi-cell stent with cells having differing characteristics.
Garvey, David S.; Letts, L. Gordon; Lin, Chia-En; Richardson, Stewart K.; Wang, Tiansheng, Nitrosated and nitrosylated taxanes, compositions and methods of use.
Landi Henry Patrick (Yorktown Heights NY) Perciaccante Vincent Anthony (Long Island City NY), Non-absorbable surgical sutures coated with polyoxyethylene-polyoxypropylene copolymer lubricant.
El-Nounou Fozan O. (Billerica MA) Savin Michael A. (Norwood MA) Sahatjian Ronald A. (Lexington MA) Weinreich Michael (Acton MA) Kordis Thomas F. (Boston MA), Percutaneous anti-migration vena cava filter.
Park Jong-Sang,KRX ; Seo Min-Hyo,KRX, Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake.
Swan Dale G. (St. Louis Park MN) Josephson Mark W. (Richfield MN) Swanson Melvin J. (Carver MN), Preparation of crosslinked matrices containing covalently immobilized chemical species and unbound releasable chemical s.
Williams Simon F. ; Martin David P. ; Gerngross Tillman ; Horowitz Daniel M., Removing endotoxin with an oxdizing agent from polyhydroxyalkanoates produced by fermentation.
Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Osborne, Thomas A.; Ragheb, Anthony O.; Roberts, Joseph W.; Voorhees, III, William D., Silver implantable medical device.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Hostettler Fritz ; Rhum David ; Forman Michael R. ; Helmus Michael N. ; Ding Ni, Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a pol.
Scott Neal A. (Atlanta GA) Hanson Stephen R. (Stone Mountain GA) King ; III Spencer B. (Atlanta GA) Harker Laurence A. (Atlanta GA), Stent sheath for local drug delivery.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GB2 ; Metcalfe James C.,GB2 ; Weissberg Peter L.,GB2 ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.